GEORGE WASHINGTON UNIVERSITY WASHINGTON (March 7, 2023)–Juvenile dermatomyositis, a rare but often severe and chronic systemic autoimmune disease, includes a large number of patients who are treatment resistant, requiring long term immunosuppressive therapy. A small open-label study published in Arthritis and Rheumatology shows promise using a targeted biologic therapy called abatacept to treat such patients. In the...
Tag: <span>dermatomyositis</span>
Post
FDA orphan drug approval: Octapharma’s Octagam(R) 10% receives 7 years of market exclusivity for adult dermatomyositis
IMAGE: OCTAPHARMA USA TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) OFFICE OF ORPHAN PRODUCTS DEVELOPMENT (OOPD) HAS AWARDED SEVEN YEARS OF MARKETING EXCLUSIVITY FOR OCTAGAM® 10% [IMMUNE GLOBULIN INTRAVENOUS (HUMAN)], THE FIRST AND ONLY INTRAVENOUS IMMUNOGLOBULIN (IVIG) TO BE INDICATED FOR THE TREATMENT OF ADULT DERMATOMYOSITIS (DM). CREDIT: OCTAPHARMA USA FDA Orphan Drug...
Post
Myositis-specific autoreactive T cells are pathogenic for dermatomyositis
UNIVERSITY OF TSUKUBA Tsukuba, Japan – Dermatomyositis is an idiopathic inflammatory myopathy that has been regarded as an autoimmunity-based disorder, although its pathogenesis remains unclear. In this study, researchers from the University of Tsukuba used a mouse model to identify a mechanism by which dermatomyositis may develop in humans. The animal model and findings can be used...